Skip to main content
MKGAF
OTC Life Sciences

FDA Approves Once-Daily Oral Therapy for Rare Joint Tumor

Tom Rudovsky · Reported by Seeking Alpha
More coverage: Healthcare
Sentiment info
Positive
Importance info
7
Price
$166.621
Mkt Cap
$73.53B
52W Low
$116.68
52W High
$175.559
52W Position info
43% above low
Off High info
5.1% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

MKGAF sits 43% above its 52-week low of $116.68.

Summary

The FDA approved Pimjetmi (pimicotinib), a once-daily oral CSF-1R inhibitor, for adults with symptomatic tenosynovial giant cell tumor where surgical resection isn't indicated. The decision rests on the Abbisko-led MANEUVER trial, which hit its primary endpoint with a statistically significant improvement in objective response rate at Week 25 versus placebo. Merck KGaA picked up global commercialization rights in December 2023 when Abbisko sold them, so this is the first U.S. green light for a drug already approved in China and Canada. It's a niche rare-disease label rather than a blockbuster, but it adds a differentiated oral option to the portfolio and validates the licensing bet. MKGAF is the primary listing; MKKGY is the same German company's ADR line.

At the time of this announcement, MKGAF was trading at $166.62 on OTC in the Life Sciences sector, with a market capitalization of approximately $73.5B. The 52-week trading range was $116.68 to $175.56. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.


Price Chart

Share this article

Copied!

MKGAF - Latest Insights